Impact of Aortic Stiffness on Further Cardiovascular Events in Patients with Chest Pain : A Invasive Study
|
|
- Aron Morrison
- 5 years ago
- Views:
Transcription
1 Impact of Aortic Stiffness on Further Cardiovascular Events in Patients with Chest Pain : A Invasive Study Cheol Ung Choi, Chang Gyu Park, Eun Bum Park, Soon Yong Suh, Jin Won Kim, Eung Ju Kim, Seung- Woon Rha, Hong Seog Seo, Dong Joo Oh, Young Moo Ro* Cardiovascular Center, Korea University Guro Hospital, Seoul, Korea, Sejong General Hospital, Bucheon*
2 Background Traditional cardiovascular risk factors :Smoking, HTN, gender, lipid profile, DM, aging have been extensivley studied Recenlty, new strong risk factor of CV diasese :Arterial stiffness have been increasingly studied
3 Association with Arterial Stiffness and CVD (Evidence based) In cross-sectional study 1. Hypertensive patients, Blacher et.al. Hypertension. 1999;33: Subjects over 70 years old Meaume et. al. J of HTN. 2001;19: In longitudinal study 1. End-stage renal disease Blacher et. al. Circulation. 1999;99: Hypertensive patients Boutouyrie et. al. Hypertension. 2002;39: Generally healthy, community-dwelling older adult Kim et al. Circulation. 2005;111: In a general Danish population Hansen et. al. Circulation.2006:113:
4 In KOREA, Cross sectional study apwv :independent risk factor of CAD and CAD severity Lim HE, Park CG et. al. Blood pressure.2004;13: However, The predictive role of aortic stiffness for further CVD in Korean patients so far?
5 Objective To determine the impact of aortic stiffness on future CV events and mortality in chest pain
6 Subject and Study Design 1004 patients with chest pain CAG and apwv Exclusion :341 pts Inclusion: 663 pts Follow-up loss : 31 pts Follow-up duration < 12months:310 pts Mean follow-up: 35 months Medical record and phone survey New cardiovascular event
7 Primary Outcome Total mortality CVD mortality New CAD Stroke CHF
8 Measurement of apwv
9 Method New CV events definitions Fatal or nonfatal acute coronary syndrome or angina Fatal or nonfatal stroke events Hospitalization for CHF
10 Method 663 pts divided into tertiles according to apwv 1) Tertile 1 (n=222) : 9.29 m/s 2) Tertile 2 (n=199) : m/s 3) Tertile 3 (n=242) : m/s Lowest tertile as a reference group
11 Demographic and Clinical Characteristics apwv Tertile Total P-value (n=222) (n=199) (n=242) (n=663) Age 54.5± ± ± ±10.2 <0.001 Male 112(50.4) 89(44.7) 126(52.1) 327(49.3) Smoking 78(35.1) 77(38.7) 142(58.7) 297(44.8) <0.001 Hx of CVD 128(57.7) 133(66.8) 169(69.8) 430(64.9) Hx of HTN 110(49.5) 113(56.8) 145(59.9) 368(55.5) 0.073
12 Demographic and Clinical Characteristics apwv Tertile Total P-value (n=222) (n=199) (n=242) (n=663) Hx of DM 24(10.8) 39(19.6) 55(22.7) 118(17.8) SBP 131.8± ± ± ±22.4 <0.001 DBP 82.1± ± ± ± Pulse pressure 49.7± ± ± ±15.0 <0.001 MAP 98.6± ± ± ±
13 Prevalence of Clinical Events According to apwv apwv Tertile 9.29 m/s m/s m/s Total Diagnosis (n=222) (n=199) (n=242) (n=663) P New CVD 45(20.3%) 48(24.1%) 80(33.1%) 176(26.1%) New CAD 34(15.3%) 29(14.6%) 60(24.8%) 123(18.6%) New stroke 7(3.2%) 15(7.5%) 15(6.2%) 37(5.6%) New CHF 4(1.8%) 6(3.0%) 6(2.5%) 16(2.4%) Revascularization 6(2.7%) 5(2.5%) 17(7.0%) 28(4.2%) Death 1(0.5%) 2(1.0%) 4(1.7%) 7(1.1%) 0.447
14 dd ratio 2.5 Univariate Analysis between Risk Factors and New CV Events $ 0 Age>60 yrs Male Smoking HTN DM SBP DBP PP MAP Diagnosis apwv apwv : apwv (>12.31m/s), PP:pulse pressure, MAP : Mean artrial pressure Diagnosis: ACS, stable angina, stroke, peripheral vascular disease(+) : 95% CI = , * : 95% $:95%CI=
15 Multivariate Analysis between Risk Factors and New CV Events Odd 2 ratio $ # Age>60 yrs Male Smoking HTN DM SBP DBP PP MAP Diagnosis apwv apwv : apwv (>12.31m/s), PP:pulse pressure, MAP : Mean artrial pressure Diagnosis: ACS, stable angina, stroke, peripheral vascular disease(+) * : 95% $:95%CI= , #:95%CI=
16 Univariate Analysis between Risk Factors and New CAD apwv : apwv (>12.31m/s), PP:pulse pressure, MAP : Mean artrial pressure Diagnosis: ACS, stable angina, stroke, peripheral vascular disease(+) * : 95% CI= Odd 2.5 ratio * Age>60yrs Male Smoking HTN DM SBP DBP PP MAP Diagnosis apwv
17 Multivariate Analysis between Risk Factors and New CAD Odd ratio * # Age>60yrs Male Smoking HTN DM SBP DBP PP MAP Diagnosis apwv apwv : apwv (>12.31m/s), PP:pulse pressure, MAP : Mean artrial pressure Diagnosis: ACS, stable angina, stroke, peripheral vascular disease(+) * : 95% CI= , #:95%CI=
18 Impact of apwv on New CVD and New CAD Odd ratio Univariate analysis Multivariate analysis apwv<9.29 apwv >12.31 apwv >12.31 apwv<9.29 apwv >12.31 apwv >12.31 New CVD New CAD
19 All-cause Mortality, Cardiovascular Mortality, CHF and Stroke 7 deaths (1 fatal MI, 1fatal stroke, 2 fatal heart failure, and 3 cancer origin) occurred. apwv was not associated with All cause mortality (p=0.447) Cardiovascular mortality (p=0.686) New CHF(p=0.718) New stroke(p=0.128)
20 Summary 1.aPWV, Age(>60), Male, DM, CVD on initial presentation was independent risk factor for new CVD 2.aPWV, Male, DM, CVD on initial presentation was independent risk factor for new CAD
21 Conclusion Aortic stiffness (apwv) 1.Patients with chest pain 2.Independent risk factor for new CV events, CAD Measuring aortic stiffness in patients with chest pain 1.Identify patients at high risk of new CV event, CAD 2.Benefit from more aggressive diagnostic as well as therapeutic strategies.
22 Limitations First, our study is confined to patients with chest pain. Thus, our findings might not be suitable to apply to the general population. Second, impact of apwv on all-cause and CV mortality is not proved sufficiently. For further study on the impact of PWV on mortality, longer follow-up time will be needed.
23 Thank you for your attention
24
Impact of Lesion Length on Chronic Total Occlusion Intervention Outcomes
Impact of Lesion Length on Chronic Total Occlusion Intervention Outcomes Seung-Woon Rha, Amro Elnagar, Byoung Geol Choi, Sung Il Im, Sun Won Kim, Jin Oh Na, Seong Woo Han, Cheol Ung Choi, Hong Euy Lim,
More informationAbstract Background: Methods: Results: Conclusions:
Two-Year Clinical and Angiographic Outcomes of Overlapping Sirolimusversus Paclitaxel- Eluting Stents in the Treatment of Diffuse Long Coronary Lesions Kang-Yin Chen 1,2, Seung-Woon Rha 1, Yong-Jian Li
More informationSeung-Woon Rha, MD, PhD FACC, FAHA, FESC, FSCAI, FAPSIC. Cardiovascular Center, Korea University Guro Hospital, Seoul, Korea.
Controversies in Acute Myocardial Infarction - Is Early Statin Therapy is Beneficial in all Patients?- : Insights from Korea Acute Myocardial Infarction Registry (KAMIR) Seung-Woon Rha, MD, PhD FACC, FAHA,
More informationKorea University Guro Hospital, Seoul, Korea * Chonnam National University Hospital, Gwangju, Korea
Left Main Disease versus Non Left Main Disease in Acute Myocardial Infarction Patients in Real world Clinical Practice : Lessons from Korea Acute Myocardial Infarction Registry (KAMIR) Seung-Woon Rha*,
More informationStatin therapy in patients with Mild to Moderate Coronary Stenosis by 64-slice Multidetector Coronary Computed Tomography
Statin therapy in patients with Mild to Moderate Coronary Stenosis by 64-slice Multidetector Coronary Computed Tomography Hyo Eun Park 1, Eun-Ju Chun 2, Sang-Il Choi 2, Soyeon Ahn 2, Hyung-Kwan Kim 3,
More information1. Diabetes mellitus (DM) is associated with worse clinical and angiographic outcomes even in acute myocardial Infarction (AMI) patients.
Midterm Clinical Outcomes of Insulin Requiring Diabetes Mellitus versus Non-insulin Dependent Diabetes Mellitus in Acute Myocardial Infarction Patients in Drug Eluting Stent Era : Insight from Korea Acute
More informationDIAMOND Study Investigators
Seung-Ho Hur, Wooyeong Jang, Jang-Whan Bae, Dong-Ju Choi, Young-Keun Ahn, Jong-Sun Park, Rak-Kyeong Choi, Dong-Hoon Choi, Joon-Hong Kim, Kyoo-Rok Han, Hun-Sik Park, So-Yeon Choi, Jung-Han Yoon, Hyeon-Cheol
More informationSupplementary Appendix
Supplementary Appendix Increased Risk of Atrial Fibrillation and Thromboembolism in Patients with Severe Psoriasis: a Nationwide Population-based Study Tae-Min Rhee, MD 1, Ji Hyun Lee, MD 2, Eue-Keun Choi,
More informationImpact of Angiotensin Converting Enzyme Inhibitor versus Angiotensin Receptor Blocker on Incidence of New-Onset Diabetes Mellitus in Asians
Original Article Yonsei Med J 2016 Jan;57(1):180-186 pissn: 0513-5796 eissn: 1976-2437 Impact of Angiotensin Converting Enzyme Inhibitor versus Angiotensin Receptor Blocker on Incidence of New-Onset Diabetes
More informationALLHAT. Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic
1 U.S. Department of Health and Human Services National Institutes of Health Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker
More informationTheoretical and practical questions in the evaluation of arterial function Miklós Illyés MD. Ph.D.
Theoretical and practical questions in the evaluation of arterial function Miklós Illyés MD. Ph.D. TensioMed Arterial Stiffness Centre, Budapest Heart Institute, Faculty of Medicine, University of Pécs
More informationBlood Pressure Targets in Diabetes
Stockholm, 29 th August 2010 ESC Meeting Blood Pressure Targets in Diabetes Peter M Nilsson, MD, PhD Department of Clinical Sciences University Hospital, Malmö Sweden Studies on BP in DM2 ADVANCE RCT (Lancet
More informationOptimal Duration of Clopidogrel Therapy with DES to Reduce Late Coronary Arterial Thrombotic Event. The DES LATE Trial
Optimal Duration of Clopidogrel Therapy with DES to Reduce Late Coronary Arterial Thrombotic Event The DES LATE Trial Cheol Whan Lee, MD, Seung-Jung Park, MD, PhD, On Behalf of the DES LATE Investigators
More informationSERUM CYSTATIN C CONCENTRATION IS A POWERFUL PROGNOSTIC INDICATOR IN PATIENTS WITH CIRRHOTIC ASCITES
SERUM CYSTATIN C CONCENTRATION IS A POWERFUL PROGNOSTIC INDICATOR IN PATIENTS WITH CIRRHOTIC ASCITES YEON SEOK SEO, 1 SOO YOUNG PARK, 2 MOON YOUNG KIM, 3 SANG GYUNE KIM, 4 JUN YONG PARK, 5 HYUNG JOON YIM,
More informationStent Fracture and Longitudinal Compression on CT Angiography between the
2014 ASCI Stent Fracture and Longitudinal Compression on CT Angiography between the First- and New-Generation Drug-Eluting Stent Mi Sun Chung, Dong Hyun Yang,Young-Hak Kim, Jae-Hyung Roh, Joon-Won Kang,
More informationCentral pressures and prediction of cardiovascular events in erectile dysfunction patients
Central pressures and prediction of cardiovascular events in erectile dysfunction patients N. Ioakeimidis, K. Rokkas, A. Angelis, Z. Kratiras, M. Abdelrasoul, C. Georgakopoulos, D. Terentes-Printzios,
More informationClinical Value of Serum Uric Acid in Patients with Suspected Coronary Artery Disease
ORIGINAL ARTICLE DOI: 10.3904/kjim.2010.25.1.21 Clinical Value of Serum Uric Acid in Patients with Suspected Coronary Artery Disease Hong Euy Lim, Seong Hwan Kim, Eung Ju Kim, Jin Won Kim, Seung Woon Rha,
More informationCoronary artery disease (CAD) risk factors
Background Coronary artery disease (CAD) risk factors CAD Risk factors Hypertension Insulin resistance /diabetes Dyslipidemia Smoking /Obesity Male gender/ Old age Atherosclerosis Arterial stiffness precedes
More informationByeong-Keuk Kim, MD, PhD. Division of Cardiology, Severance Cardiovascular Hospital Yonsei University College of Medicine, Seoul, Korea
Byeong-Keuk Kim, MD, PhD Division of Cardiology, Severance Cardiovascular Hospital Yonsei University College of Medicine, Seoul, Korea BP change (mmhg) from Baseline to 6 Months (mmhg) Catheter-based renal
More informationRevascularization after Drug-Eluting Stent Implantation or Coronary Artery Bypass Surgery for Multivessel Coronary Disease
Impact of Angiographic Complete Revascularization after Drug-Eluting Stent Implantation or Coronary Artery Bypass Surgery for Multivessel Coronary Disease Young-Hak Kim, Duk-Woo Park, Jong-Young Lee, Won-Jang
More informationsurtout qui n est PAS à risque?
3*25 min et surtout qui n est PAS à risque? 2018 ESC/ESH Hypertension Guidelines 2018 ESC-ESH Guidelines for the Management of Arterial Hypertension 28 th ESH Meeting on Hypertension and Cardiovascular
More informationThe earlier BP control the better cardiovascular outcome. Jin Oh Na Cardiovascular center Korea University Medical College
The earlier BP control the better cardiovascular outcome Jin Oh Na Cardiovascular center Korea University Medical College Index Introduction HOPE-3 Trial Sprint Study Summary Each 2 mmhg decrease in SBP
More informationThe Diabetes Link to Heart Disease
The Diabetes Link to Heart Disease Anthony Abe DeSantis, MD September 18, 2015 University of WA Division of Metabolism, Endocrinology and Nutrition Oswald Toosweet Case #1 68 yo M with T2DM Diagnosed DM
More informationNon-cardiac Procedures and
Non-cardiac Procedures and Surgery after Drug-Eluting Stent Implantation Seung-Woon Rha, MD, PhD, FACC, FAHA, FSCAI, FESC, FAPSIC Div of Cardiovascular Intervention and Research Cardiovascular Center,
More informationSeung Hyeok Han, MD, PhD Department of Internal Medicine Yonsei University College of Medicine
Seung Hyeok Han, MD, PhD Department of Internal Medicine Yonsei University College of Medicine The Scope of Optimal BP BP Reduction CV outcomes & mortality CKD progression - Albuminuria - egfr decline
More informationArterial function and longevity Focus on the aorta
Arterial function and longevity Focus on the aorta Panagiota Pietri, MD, PhD, FESC Director of Hypertension Unit Athens Medical Center Athens, Greece Secrets of longevity Secrets of longevity Unveiling
More informationManaging HTN in the Elderly: How Low to Go
Managing HTN in the Elderly: How Low to Go Laxmi S. Mehta, MD, FACC The Ohio State University Medical Center Assistant Professor of Clinical Internal Medicine Clinical Director of the Women s Cardiovascular
More informationAcute Myocardial Infarction Patients
Role of Pitavastatin (Livalo ) in Asian Acute Myocardial Infarction Patients : Insights from Livalo Acute Myocardial Infarction Study (LAMIS) Seung-Woon Rha, MD, PhD FACC, FAHA, FESC, FSCAI, FAPSIC Cardiovascular
More informationAPPENDIX D: PHARMACOTYHERAPY EVIDENCE
Página 1 de 7 APPENDIX D: PHARMACOTYHERAPY EVIDENCE Table D1. Outcome Trials of Antihypertensive Agents Study Drug Regimen N Duration Primary Outcomes Remarks Antihypertensive Therapy vs Placebo SHEP 1991
More informationCauses of death in Diabetes
Rates of CV events in Diabetes patients Respiratory4.2 Cancer 7.6 Diabetes 1.3 CV disease 17.3 Causes of death in Diabetes 250 200 150 100 50 0 per 10,000 person-years 97 151 243 Framingham 5 X increase
More informationSupplement materials:
Supplement materials: Table S1: ICD-9 codes used to define prevalent comorbid conditions and incident conditions Comorbid condition ICD-9 code Hypertension 401-405 Diabetes mellitus 250.x Myocardial infarction
More informationBlood pressure treatment target in diabetes. Should it be <130 mmhg?
Blood pressure treatment target in diabetes Should it be
More informationCardiovascular Outcomes With Newer Diabetes Drugs: Results From The EMPA-REG and LEADER Trials
Cardiovascular Outcomes With Newer Diabetes Drugs: Results From The EMPA-REG and LEADER Trials Rajiv Roy, MD Endocrinology Sharp Rees-Stealy Medical Group Background Between 1990 and 2010: Incidence of
More informationThe Effect of Isosorbide Dinitrate Intravenous Injection on the Hemodynamics and Arterial Stiffness of Patients with Isolated Systolic Hypertension
Original ORIGINAL Article ARTICLE Korean Circulation J 2007;37:359-364 ISSN 1738-5520 c 2007, The Korean Society of Circulation The Effect of Isosorbide Dinitrate Intravenous Injection on the Hemodynamics
More informationRemodeling of the Remnant Aorta after Acute Type A Aortic Dissection Surgery
Remodeling of the Remnant Aorta after Acute Type A Aortic Dissection Surgery Are Young Patients More Likely to Develop Adverse Aortic Remodeling of the Remnant Aorta Over Time? Suk Jung Choo¹, Jihoon Kim¹,
More informationIncidence and Predictors of Stent Thrombosis after Percutaneous Coronary Intervention in Acute Myocardial Infarction
Incidence and Predictors of Stent Thrombosis after Percutaneous Coronary Intervention in Acute Myocardial Infarction Sungmin Lim, Yoon Seok Koh, Hee Yeol Kim, Ik Jun Choi, Eun Ho Choo, Jin Jin Kim, Mineok
More informationSoo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital
Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital 1. Importance of Lowering LDL-Cholesterol in Diabetes Patients & Lipid Guidelines Prevalence of dyslipidemia in Korea Prevalence
More information2017 Obesity Fact Sheet
2017 Fact Sheet Welcome message 2017 Fact Sheet Dear Colleagues, It is my great honor and pleasure to publish the 2017 Fact Sheet of the Korean Society for the Study of (KSSO). The 2017 Fact Sheet is the
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More informationHYPERTENSION GUIDELINES WHERE ARE WE IN 2014
HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University
More informationThe TNT Trial Is It Time to Shift Our Goals in Clinical
The TNT Trial Is It Time to Shift Our Goals in Clinical Angioplasty Summit Luncheon Symposium Korea Assoc Prof David Colquhoun 29 April 2005 University of Queensland, Wesley Hospital, Brisbane, Australia
More informationIs it ever too late for cardiovascular prevention and rehabilitation? Prof. Dr. Helmut Gohlke Herz-Zentrum Bad Krozingen, Germany
Is it ever too late for cardiovascular prevention and rehabilitation? Prof. Dr. Helmut Gohlke Herz-Zentrum Bad Krozingen, Germany The demographic issue Life expectancy is increasing Patients are getting
More informationDong Joo Oh 1, Su-Eun Han 2, Seung Hee Jeong 2, Myung Sook Hong 2 and Seong Choon Choe 2*
Oh et al. Clinical Hypertension (2018) 24:10 https://doi.org/10.1186/s40885-018-0096-2 RESEARCH Open Access Clinical characteristics and satisfaction with the fimasartan in Korean hypertensive patients:
More informationDECISION-CTO. Optimal Medical Therapy With or Without Stenting For Coronary Chronic Total Occlusion. Seung-Jung Park, MD., PhD.
DECISION-CTO Optimal Medical Therapy With or Without Stenting For Coronary Chronic Total Occlusion Seung-Jung Park, MD., PhD. Heart Institute, University of Ulsan College of Medicine Asan Medical Center,
More informationBackground. Metabolic syndrome T2DM CARDIOVASCULAR DISEASE. Major Unmet Clinical Need. Novel Risk Factors. Classical Risk Factors LDL-C.
The effect of metabolic syndrome for left ventricular geometry, arterial stiffness and carotid intima-media thickness in Korean general population Result from Atherosclerosis RIsk of Rural Area in Korea
More informationCentral hemodynamics and prediction of cardiovascular events in patients with erectile dysfunction
Central hemodynamics and prediction of cardiovascular events in patients with erectile dysfunction N.Skliros, N.Ioakeimidis, D.Terentes-Printzios, C.Vlachopoulos Cardiovascular Diseases and Sexual Health
More information4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS?
HYPERTENSION TARGETS: WHAT DO WE DO NOW? MICHAEL LEFEVRE, MD, MSPH PROFESSOR AND VICE CHAIR DEPARTMENT OF FAMILY AND COMMUNITY MEDICINE UNIVERSITY OF MISSOURI 4/4/17 DISCLOSURE: MEMBER OF THE JNC 8 PANEL
More informationHypertension Management Controversies in the Elderly Patient
Hypertension Management Controversies in the Elderly Patient Juan Bowen, MD Geriatric Update for the Primary Care Provider November 17, 2016 2016 MFMER slide-1 Disclosure No financial relationships No
More informationTreating Hypertension in 2018: What Makes the Most Sense Today?
Treating Hypertension in 2018: What Makes the Most Sense Today? Daniel Blanchard, MD Professor of Medicine UC San Diego Cardiovascular Center La Jolla, California 1 2 Speaker Disclosures Consultant and/or
More informationBlood Pressure Treatment Goals
Blood Pressure Treatment Goals Kenneth Izuora, MD, MBA, FACE Associate Professor UNLV School of Medicine November 18, 2017 Learning Objectives Discuss the recent studies on treating hypertension Review
More informationPCI vs. CABG From BARI to Syntax, Is The Game Over?
PCI vs. CABG From BARI to Syntax, Is The Game Over? Seung-Jung Park, MD, PhD Professor of Medicine, University of Ulsan College of Medicine Asan Medical Center, Seoul, Korea PCI vs CABG Multi-Vessel Disease
More informationHypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic
Hypertension in 2015: SPRINT-ing ahead of JNC-8 MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic Conflits of interest? None Disclaimer The opinions contained herein are not to be considered
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationConsensus document: Screening and Prevention of Atrial Fibrillation
Consensus document: Screening and Prevention of Atrial Fibrillation Yong-Seog Oh, M.D.,Ph.D. Division of Cardiology, Department of Internal Medicine, Seoul St. Mary s Hospital, College of Medicine, The
More informationPlacebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationHypertension and the SPRINT Trial: Is Lower Better
Hypertension and the SPRINT Trial: Is Lower Better 8th Annual Orange County Symposium on Cardiovascular Disease Prevention Saturday, October 8, 2016 Keith C. Norris, MD, PhD, FASN Professor of Medicine,
More informationMean INTERHEART Risk Score (IHRS) Yusuf et al NEJM 2014
Mean INTERHEART Risk Score (IHRS) Yusuf et al NEJM 2014 CVD Event Rates Major CVD = death from CV causes, stroke, MI and HF Non major CVD = all other CVD events that led to hospitalization Yusuf et al
More informationUnprotected LM intervention
Unprotected LM intervention Guideline for COMBAT Seung-Jung Park, MD, PhD Professor of Internal Medicine, Seoul, Korea Current Recommendation for unprotected LMCA Stenosis Class IIb C in ESC guideline
More informationPlacebo-Controlled Statin Trials Prevention Of CVD in Women"
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationLipid Management 2013 Statin Benefit Groups
Clinical Integration Steering Committee Clinical Integration Chronic Disease Management Work Group Lipid Management 2013 Statin Benefit Groups Approved by Board Chair Signature Name (Please Print) Date
More informationROLE OF INFLAMMATION IN HYPERTENSION. Dr Barasa FA Physician Cardiologist Eldoret
ROLE OF INFLAMMATION IN HYPERTENSION Dr Barasa FA Physician Cardiologist Eldoret Outline Inflammation in CVDs the evidence Basic Science in Cardiovascular inflammation: The Main players Inflammation as
More informationHypertension: What s new since JNC 7. Harold M. Szerlip, MD, FACP, FCCP, FASN, FNKF
Hypertension: What s new since JNC 7 Harold M. Szerlip, MD, FACP, FCCP, FASN, FNKF Disclosures Spectral Diagnostics Site investigator Eli Lilly Site investigator ACP IM ITE writing committee NBME Step
More informationPrevention of MACROvascular Complications of Diabetes
Prevention of MACROvascular Complications of Diabetes Matt Bouchonville, MD, CDE Endocrinology Division University of New Mexico School of Medicine July 12, 2018 Conflicts of Interest None Objectives 1.
More informationIs it worth offering cardiovascular disease prevention to the elderly? Prof. Dr. Helmut Gohlke Herz-Zentrum Bad Krozingen, Germany
Is it worth offering cardiovascular disease prevention to the elderly? Prof. Dr. Helmut Gohlke Herz-Zentrum Bad Krozingen, Germany Is it worth offering cardiovascular disease prevention to the elderly?
More informationThe presenter does not have any potential conflicts of interest to disclose
Carotid intima-media thickness as a predictor of multi territory atherosclerotic occlusive disease in patients with symptomatic subclavian artery obstruction Leszek Wrotniak 1, Anna Kabłak Ziembicka 1,
More information9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t?
Primary Prevention of Heart Disease: What works? What doesn t? Samia Mora, MD, MHS Associate Professor, Harvard Medical School Associate Physician, Brigham and Women s Hospital October 2, 2015 Financial
More informationEyes on Korean Data: Lipid Management in Korean DM Patients
Eyes on Korean Data: Lipid Management in Korean DM Patients ICDM Luncheon Symposium Sung Rae Kim MD PhD Division of Endocrinology and Metabolism The Catholic University of Korea Causes of Death in People
More informationLDL cholesterol and cardiovascular outcomes?
LDL cholesterol and cardiovascular outcomes? Prof Kausik Ray, BSc (hons), MBChB, FRCP, MD, MPhil (Cantab), FACC, FESC Professor of Cardiovascular Disease Prevention St Georges University of London Honorary
More informationDiabetes Mellitus: A Cardiovascular Disease
Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular
More information1. How does the response to therapy compare in elderly versus middle age adults with diabetes in a randomized trial?
Jeff D. Williamson, MD, MHS Chief, Geriatric Medicine Sticht Center on Aging 1. How does the response to therapy compare in elderly versus middle age adults with diabetes in a randomized trial? 2. Are
More informationThe MAIN-COMPARE Registry
Long-Term Outcomes of Coronary Stent Implantation versus Bypass Surgery for the Treatment of Unprotected Left Main Coronary Artery Disease Revascularization for Unprotected Left MAIN Coronary Artery Stenosis:
More informationShould we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway
Should we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway The Polypill A strategy to reduce cardiovascular disease by
More informationJNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH
JNC 8 -Controversies Sagren Naidoo Nephrologist CMJAH Joint National Committee (JNC) Panel appointed by the National Heart, Lung, and Blood Institute (NHLBI) First guidelines (JNC-1) published in 1977
More informationUricemia nei pazienti a. fattore o marker di rischio? Claudio Borghi, FESC, FAHA Dipartimento di Scienze Mediche e Chirurgiche Università di Bologna
Uricemia nei pazienti a rischio CV: fattore o marker di rischio? Claudio Borghi, FESC, FAHA Dipartimento di Scienze Mediche e Chirurgiche Università di Bologna R.Magritte: La reproducion interdite Urate
More informationΠρώιμη αγγειακή γήρανση στην υπέρταση: διάγνωση και αντιμετώπιση
Πρώιμη αγγειακή γήρανση στην υπέρταση: διάγνωση και αντιμετώπιση Χαράλαμπος Βλαχόπουλος 1 η Καρδιολογική Κλινική Πανεπιστημίου Αθηνών Ιπποκράτειο Γ.Ν.Α. Οι προβλεπόμενες αρτηριακές αλλαγές με βάση την
More informationwell-targeted primary prevention of cardiovascular disease: an underused high-value intervention?
well-targeted primary prevention of cardiovascular disease: an underused high-value intervention? Rod Jackson University of Auckland, New Zealand October 2015 Lancet 1999; 353: 1547-57 Findings: Contribution
More informationClinical application of Arterial stiffness. pulse wave analysis pulse wave velocity
Clinical application of Arterial stiffness pulse wave analysis pulse wave velocity Arterial system 1. Large arteries: elastic arteries Aorta, carotid, iliac, Buffering reserve: store blood during systole
More informationJAMA. 2011;305(24): Nora A. Kalagi, MSc
JAMA. 2011;305(24):2556-2564 By Nora A. Kalagi, MSc Cardiovascular disease (CVD) is the number one cause of mortality and morbidity world wide Reducing high blood cholesterol which is a risk factor for
More informationVascular disease. Structural evaluation of vascular disease. Goo-Yeong Cho, MD, PhD Seoul National University Bundang Hospital
Vascular disease. Structural evaluation of vascular disease Goo-Yeong Cho, MD, PhD Seoul National University Bundang Hospital resistance vessels : arteries
More informationDECLARATION OF CONFLICT OF INTEREST. None
DECLARATION OF CONFLICT OF INTEREST None How low should we go to avoid harm in hypertensives with comorbidities? CORONARY ARTERY DISEASE Prof. Dr. Maria DOROBANTU, FESC,FACC CARDIOLOGY EMERGENCY HOSPITAL
More informationCentral Pressures and Prehypertension
Central Pressures and Prehypertension Charalambos Vlachopoulos Associate Professor of Cardiology 1 st Cardiology Dept Athens Medical School Central Pressures and Prehypertension Charalambos Vlachopoulos
More informationClinical Features and Subtypes of Ischemic Stroke Associated with Peripheral Arterial Disease
Cronicon OPEN ACCESS EC NEUROLOGY Research Article Clinical Features and Subtypes of Ischemic Stroke Associated with Peripheral Arterial Disease Jin Ok Kim, Hyung-IL Kim, Jae Guk Kim, Hanna Choi, Sung-Yeon
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More informationThe Relationship Between the Acute Changes of the Systolic Blood Pressure and the Brachial-Ankle Pulse Wave Velocity
The Korean Journal of Internal Medicine : 22:147-151, 2007 The Relationship Between the Acute Changes of the Systolic Blood Pressure and the Brachial-Ankle Pulse Wave Velocity Hun-Jun Park, M.D., Tai-Ho
More informationJ-curve Revisited. An Analysis of Blood Pressure and Cardiovascular Events in the Treating to New Targets (TNT) Trial
J-curve Revisited An Analysis of Blood Pressure and Cardiovascular Events in the Treating to New Targets (TNT) Trial Sripal Bangalore, MD, MHA, Franz H Messerli, MD, Chuan-Chuan Wun, PhD, Andrea L. Zuckerman,
More informationCorrelation of LV Longitudinal Strain by 2D Speckle Tracking with Cardiovascular risk in Elderly. (A pilot study of EGAT-Echo study.
Correlation of LV Longitudinal Strain by 2D Speckle Tracking with Cardiovascular risk in Elderly. (A pilot study of EGAT-Echo study.) Researcher: Dr. Atthakorn Wutthimanop, MD. Research adviser: Dr.PrinVathesathokit,
More informationThe Beneficial Role of Angiotensin- Converting Enzyme Inhibitor in Acute Myocardial Infarction
The Beneficial Role of Angiotensin- Converting Enzyme Inhibitor in Acute Myocardial Infarction Cardiovascular Center, Korea University Guro Hospital 2007. 4. 20 Seung-Woon Rha, MD, PhD Introduction 1.
More informationThe MAIN-COMPARE Study
Long-Term Outcomes of Coronary Stent Implantation versus Bypass Surgery for the Treatment of Unprotected Left Main Coronary Artery Disease Revascularization for Unprotected Left MAIN Coronary Artery Stenosis:
More informationImplications of Drug-related Increases in Blood Pressure
Implications of Drug-related Increases in Blood Pressure Preston M. Dunnmon, MD, FACP, FACC Division of Cardiovascular and Renal Products US Food and Drug Administration July 18, 2012 Disclaimer The findings
More informationADVANCE post trial ObservatioNal Study
Hot Topics in Diabetes 50 th EASD, Vienna 2014 ADVANCE post trial ObservatioNal Study Sophia Zoungas The George Institute The University of Sydney Rationale and Study Design Sophia Zoungas The George Institute
More informationTreating Hypertension in Individuals with Diabetes
Treating Hypertension in Individuals with Diabetes Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any
More informationBLOOD PRESSURE-LOWERING TREATMENT
BLOOD PRESSURE-LOWERING TRIALS NUMBER OF PARTICIPANTS NUMBER OF PERCENTAGE OF MEAN AGE MEAN - (YEARS) TRIALS WITH ANALYSIS BY GENDER N, (%) 69,473 28,008 40.3% 70.2 3.2 3/5 (60%) APPENDIX 2 1 BLOOD PRESSURE-LOWERING
More informationAsian AMI Registry Session The 17 th Joint Meeting of Coronary Revascularization (JCR 2017) Busan, Korea Dec 8 th 2017
Asian AMI Registry Session The 17 th Joint Meeting of Coronary Revascularization (JCR 2017) Busan, Korea Dec 8 th 2017 Trends of acute myocardial infarction in Korea from the experience of Korea Acute
More informationAssociation between arterial stiffness and cardiovascular risk factors in a pediatric population
+ Association between arterial stiffness and cardiovascular risk factors in a pediatric population Maria Perticone Department of Experimental and Clinical Medicine University Magna Graecia of Catanzaro
More informationHypertension Update 2009
Hypertension Update 2009 New Drugs, New Goals, New Approaches, New Lessons from Clinical Trials Timothy C Fagan, MD, FACP Professor Emeritus University of Arizona New Drugs Direct Renin Inhibitors Endothelin
More informationRenal Artery FFR. Woo-Young Chung. Seoul National University, College of Medicine Boramae Medical Center Cardiovascular Center
Renal Artery FFR Woo-Young Chung Seoul National University, College of Medicine Boramae Medical Center Cardiovascular Center Why renal FFR? Renal artery angioplasty (PTRA) Indication of Renal artery angioplasty
More informationEstrogens vs Testosterone for cardiovascular health and longevity
Estrogens vs Testosterone for cardiovascular health and longevity Panagiota Pietri, MD, PhD, FESC Director of Hypertension Unit Athens Medical Center Athens, Greece Women vs Men Is there a difference in
More informationThe Brachial Ankle Pulse Wave Velocity is Associated with the Presence of Significant Coronary Artery Disease but Not the Extent
Original Article Print ISSN 1738-5520 On-line ISSN 1738-5555 Korean Circulation Journal The Brachial Ankle Pulse Wave Velocity is Associated with the Presence of Significant Coronary Artery Disease but
More informationPatient is healthy with no chronic disease or significant risk factors [16%].
AAFP Risk Level 1 Patient is healthy with no chronic disease or significant risk factors [16%]. Exclude the following chronic problems from active patient list o Depression o Diabetes Type I or Type II
More information